• EZ Cap™ Firefly Luciferase mRNA: Precision Reporter Advances

  2026-07-07

  EZ Cap™ Firefly Luciferase mRNA, engineered with a Cap 1 structure and optimized poly(A) tail, dramatically enhances mRNA stability and translation for reporter assays. This product delivers robust, sustained bioluminescent signals suitable for gene regulation and in vivo imaging applications. Its design aligns with modern mRNA delivery strategies, enabling reliable data in translational and molecular biology workflows.

• Firefly Luciferase mRNA (5-moUTP): Applied Workflows & Optim

  2026-07-06

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) accelerates high-sensitivity reporter assays and gene delivery studies with its Cap 1 structure and 5-moUTP modification, providing enhanced stability and low immunogenicity. This article distills advanced experimental workflows, troubleshooting strategies, and translational insights—bridging bench protocols with next-generation immune-modulatory delivery innovations.

• JZL184: Optimizing Monoacylglycerol Lipase Inhibitor Workflo

  2026-07-06

  JZL184 stands out as a gold-standard monoacylglycerol lipase inhibitor, enabling precise modulation of endocannabinoid signaling in both acute and chronic pain studies. This guide delivers actionable protocols, advanced troubleshooting, and unique translational insights derived from cutting-edge research—empowering next-generation neuropharmacology and behavioral science.

• IRG1-Itaconic Acid Axis Inhibits TBK1-Driven Type I IFN Resp

  2026-07-05

  Chai et al. uncover how the IRG1-itaconic acid axis links cellular metabolism to innate immunity by alkylating TBK1, thereby restraining type I interferon responses. Their development of targeted itaconic acid derivatives (ITA-5 and ITA-9) offers new strategies for modulating hyperinflammatory states.

• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate f

  2026-07-04

  This study introduces a streamlined 13-step protocol for synthesizing deuterium-labeled degarelix acetate, enabling robust internal standards for pharmacokinetic and metabolic research on GnRH receptor antagonists. The method improves yield, reliability, and supports advanced clinical investigations in androgen-related diseases.

• IWP-2: Potent Wnt Production Inhibitor in Cancer Research

  2026-07-03

  IWP-2 is a highly potent Wnt production inhibitor that targets Porcupine (Porcn), disrupting Wnt/β-catenin signaling crucial in oncogenesis and development. Its robust in vitro and in vivo efficacy, precise mechanism, and well-characterized properties make it a benchmark tool for cancer research and apoptosis assays.

• Rucaparib, Spliceosome Acetylation, and DNA Repair Strategy

  2026-07-03

  This thought-leadership article explores how Rucaparib (AG-014699) is redefining translational cancer research by bridging PARP inhibition with emerging mechanistic insights into spliceosome acetylation. Drawing on new findings in hepatocellular carcinoma (HCC) and advanced prostate cancer, we detail protocol strategies, competitive context, and translational directions for researchers aiming to expand PARP inhibitor applications beyond BRCA-deficient cancers.

• Betulinic Acid Mitigates Cyclophosphamide-Induced Liver Dama

  2026-07-02

  This study reveals that betulinic acid (BA) reduces cyclophosphamide-induced oxidative stress and hepatotoxicity in mice by modulating the NRF2 antioxidant and ERK–MAPK apoptotic pathways. Through mechanistic dissection, the research demonstrates that both BA and the MEK inhibitor PD98059 confer hepatic protection by targeting ERK-mediated mitochondrial apoptosis, suggesting translational potential for adjunctive therapies in CYP-associated liver injury.

• Tirbanibulin Downregulates HPV Oncoproteins and Promotes Apo

  2026-07-02

  This study demonstrates that tirbanibulin significantly inhibits cell proliferation and downregulates oncogenic pathway proteins, including HPV-18 E6/E7, in HeLa cells. The findings highlight tirbanibulin’s multifaceted mechanism in modulating Src-MEK signaling and apoptosis, offering translational insight for HPV-associated cancer research.

• AngII Drives M1 Macrophage Polarization via Cx43/NF-κB Pathw

  2026-07-01

  This study demonstrates that angiotensin II (AngII) induces M1-type polarization in RAW264.7 macrophages through the connexin 43 (Cx43)/NF-κB signaling pathway. The findings provide mechanistic insight into inflammation in cardiovascular disease and highlight the utility of selective Cx43 hemichannel blockers for dissecting immune signaling.

• Sodium Oxamate in Tumor and Viral Metabolism: Applied Workfl

  2026-07-01

  Sodium Oxamate, a potent LDH-A inhibitor, empowers metabolic reprogramming research in both cancer and viral infection models. This guide delivers actionable protocols, troubleshooting strategies, and translational insights, highlighting APExBIO’s trusted product as a bridge between tumor bioenergetics and innate immune modulation.

• DOT1L Inhibition Primes Innate Immunity to Boost Lenalidomid

  2026-06-30

  This study demonstrates that inhibiting DOT1L, a key epigenetic regulator, reprograms innate immune signaling in multiple myeloma and markedly enhances the anti-tumor efficacy of immunomodulatory drugs such as lenalidomide. The findings suggest a new therapeutic axis that leverages both epigenetic and immune mechanisms to improve outcomes in refractory multiple myeloma.

• L-Glutathione Reduced: Redox Regulation and GOT1-Targeted As

  2026-06-30

  Explore the scientific foundations and advanced applications of L-Glutathione Reduced as a redox regulator and assay standard in cancer metabolism research. This article delivers expert insights into GOT1-linked protocols, unique mechanistic analysis, and translational relevance.

• DiscoveryProbe™ Metabolism-related Compound Library: Practic

  2026-06-29

  The DiscoveryProbe™ Metabolism-related Compound Library offers a rigorously validated set of 493 bioactive small molecules to streamline metabolic enzyme inhibition, pathway mapping, and disease-focused research in vitro and ex vivo. This product is optimized for high-throughput, cell-based, and biochemical workflows, but is not suitable for diagnostic, clinical, or in vivo therapeutic use.

• EZ Cap™ Human PTEN mRNA (ψUTP): Redefining Immune-Evasive Ge

  2026-06-29

  Discover how EZ Cap™ Human PTEN mRNA (ψUTP) advances in vitro transcribed mRNA research, offering unprecedented stability and immune evasion for robust tumor suppressor restoration. This article uniquely explores the intersection of molecular engineering and translational strategy, illuminating practical and mechanistic insights beyond standard protocols.

17124 records 6/1142 page Previous Next First page 上5页 678910 下5页 Last page